Why is Sun Pharmaceutical Industries Ltd ?
1
Low Debt Company with Strong Long Term Fundamental Strength
- Healthy long term growth as Net Sales has grown by an annual rate of 11.10% and Operating profit at 21.96%
- Company has a low Debt to Equity ratio (avg) at 0 times
- The company has been able to generate a Return on Equity (avg) of 15.21% signifying high profitability per unit of shareholders funds
2
Positive results in Sep 25
- OPERATING CF(Y) Highest at Rs 4,198.77 Cr
- DPS(Y) Highest at Rs 16.00
- CASH AND CASH EQUIVALENTS(HY) Highest at Rs 122,574.20 cr
3
High Institutional Holdings at 36.79%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
5
With its market cap of Rs 4,36,343 cr, it is the biggest company in the sector and constitutes 18.35% of the entire sector
- Its annual Sales of Rs 54,964.01 are 12.04% of the industry
How much should you buy?
- Overall Portfolio exposure to Sun Pharma.Inds. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sun Pharma.Inds. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sun Pharma.Inds.
-0.26%
-0.01
19.76%
Sensex
4.83%
0.41
11.83%
Quality key factors
Factor
Value
Sales Growth (5y)
11.10%
EBIT Growth (5y)
21.96%
EBIT to Interest (avg)
58.10
Debt to EBITDA (avg)
0.28
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.71
Tax Ratio
25.25%
Dividend Payout Ratio
35.13%
Pledged Shares
0.97%
Institutional Holding
36.79%
ROCE (avg)
21.14%
ROE (avg)
15.21%
Valuation Key Factors 
Factor
Value
P/E Ratio
38
Industry P/E
34
Price to Book Value
5.57
EV to EBIT
29.68
EV to EBITDA
24.79
EV to Capital Employed
7.44
EV to Sales
7.47
PEG Ratio
12.41
Dividend Yield
0.89%
ROCE (Latest)
25.07%
ROE (Latest)
14.84%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Technical Movement
11What is working for the Company
OPERATING CF(Y)
Highest at Rs 4,198.77 Cr
DPS(Y)
Highest at Rs 16.00
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 122,574.20 cr
NET SALES(Q)
Highest at Rs 14,478.31 cr
PBDIT(Q)
Highest at Rs 4,527.05 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 31.27%
PBT LESS OI(Q)
Highest at Rs 3,697.69 cr.
EPS(Q)
Highest at Rs 13.00
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.35 times
Loading Valuation Snapshot...
Here's what is working for Sun Pharma.Inds.
Operating Cash Flow - Annually
Highest at Rs 4,198.77 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Dividend per Share (DPS) - Annually
Highest at Rs 16.00 and Grown
each year in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (Rs)
Net Sales - Quarterly
Highest at Rs 14,478.31 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 4,527.05 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 31.27%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 3,697.69 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 13.00
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 122,574.20 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Sun Pharma.Inds.
Debtors Turnover Ratio- Half Yearly
Lowest at 0.35 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio






